NCT03061331View on ClinicalTrials.gov

Lumacaftor/Ivacaftor Combination Therapy in Subjects With CF Who Have an A455E CFTR Mutation

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

September 6, 2017

Study Completion Date

October 4, 2017

Conditions
Cystic Fibrosis
Interventions
DRUG

LUM/IVA

LUM 400 mg/IVA 250 mg every 12 hours (q12h)

DRUG

Placebo

No Active Drug

Trial Locations (2)

Unknown

University Medical Center, Utrecht, Department of Pulmonology and Tuberculosis, Heidelberglaan

HagaZiekenhuis, The Hague

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT03061331 - Lumacaftor/Ivacaftor Combination Therapy in Subjects With CF Who Have an A455E CFTR Mutation | Biotech Hunter | Biotech Hunter